Edition:
United Kingdom

Kubota Pharmaceutical Holdings Co Ltd (4596.T)

4596.T on Tokyo Stock Exchange

536JPY
23 Feb 2018
Change (% chg)

¥9 (+1.71%)
Prev Close
¥527
Open
¥524
Day's High
¥540
Day's Low
¥524
Volume
37,800
Avg. Vol
144,739
52-wk High
¥933
52-wk Low
¥494

Latest Key Developments (Source: Significant Developments)

Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd <4596.T>:Says co's wholly owned unit Acucela Inc signed a two-year development agreement with gene delivery expert SIRION Biotech GmbH (SIRION) to establish optimized AAV vectors for clinical applications in ocular gene therapy.Says Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa.Key terms of the agreement include milestone payments to SIRION, with additional royalties to be paid on net sales from resulting products or therapies.  Full Article

Kubota Pharmaceutical Holdings says unit Acucela receives patent covering method of use for emixustat hydrochloride
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd <4596.T>:* Says unit Acucela Inc received a patent (No. 9,737,496 B2) covering method of use for emixustat hydrochloride from the United States Patent and Trademark Office (USPTO) .  Full Article

SBI Holdings sells all stake in Kubota Pharmaceutical Holdings
Thursday, 16 Mar 2017 

Kubota Pharmaceutical Holdings Co Ltd <4596.T> :Says 3rd biggest shareholder SBI Holdings, Inc. sold all 6,196,869 shares in the company on Feb. 28.  Full Article

BRIEF-Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy

* Says co's wholly owned unit Acucela Inc signed a two-year development agreement with gene delivery expert SIRION Biotech GmbH (SIRION) to establish optimized AAV vectors for clinical applications in ocular gene therapy